![Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database | Scientific Reports Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-85389-x/MediaObjects/41598_2021_85389_Fig1_HTML.png)
Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database | Scientific Reports
![Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/31/19/7190/F4.large.jpg)
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) EnantiomersIn Vitroand in the MPTP-Lesioned Primate:R-MDMA Reduces
![Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers In Vitro and in the MPTP-Lesioned Primate: R-MDMA Reduces Severity of Dyskinesia, Whereas S-MDMA Extends Duration of ON-Time | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/31/19/7190/F1.large.jpg)